Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan.
Tsuchihashi K, Ito M, Arita S, Kusaba H, Kusano W, Matsumura T, Kitazono T, Ueno S, Taguchi R, Yoshihiro T, Doi Y, Arimizu K, Ohmura H, Kajitani T, Nio K, Nakano M, Oshima K, Tamura S, Shirakawa T, Shimokawa H, Uchino K, Hanamura F, Okumura Y, Komoda M, Isobe T, Ariyama H, Esaki T, Hashimoto K, Komune N, Matsuo M, Matsumoto K, Asai K, Yoshitake T, Yamamoto H, Oda Y, Akashi K, Baba E. Tsuchihashi K, et al. Among authors: ariyama h. BMC Cancer. 2023 Oct 31;23(1):1046. doi: 10.1186/s12885-023-11528-4. BMC Cancer. 2023. PMID: 37904096 Free PMC article.
Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).
Okuma HS, Watanabe K, Tsuchihashi K, Machida R, Sadachi R, Hirakawa A, Ariyama H, Kanai M, Kamikura M, Anjo K, Hiramitsu A, Sekine S, Okita N, Mano H, Nishikawa H, Nakamura K, Yonemori K. Okuma HS, et al. Among authors: ariyama h. Clin Cancer Res. 2023 Dec 15;29(24):5079-5086. doi: 10.1158/1078-0432.CCR-23-1807. Clin Cancer Res. 2023. PMID: 37819940 Free PMC article. Clinical Trial.
Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions.
Uehara K, Tanoue K, Yamaguchi K, Ohmura H, Ito M, Matsushita Y, Tsuchihashi K, Tamura S, Shimokawa H, Isobe T, Shibata Y, Ariyama H, Tanaka R, Kusaba H, Yamamoto H, Oda Y, Akashi K, Baba E. Uehara K, et al. Among authors: ariyama h. Cancer Immunol Immunother. 2023 Nov;72(11):3543-3558. doi: 10.1007/s00262-023-03505-4. Epub 2023 Aug 7. Cancer Immunol Immunother. 2023. PMID: 37550428 Free PMC article.
Division in synthetic cells.
Chang MY, Ariyama H, Huck WTS, Deng NN. Chang MY, et al. Among authors: ariyama h. Chem Soc Rev. 2023 May 22;52(10):3307-3325. doi: 10.1039/d2cs00985d. Chem Soc Rev. 2023. PMID: 37066696 Review.
RHAMM marks proliferative subpopulation of human colorectal cancer stem cells.
Nakano M, Taguchi R, Kikushige Y, Isobe T, Miyawaki K, Mizuno S, Tsuruta N, Hanamura F, Yamaguchi K, Yamauchi T, Ariyama H, Kusaba H, Nakamura M, Maeda T, Kuo CJ, Baba E, Akashi K. Nakano M, et al. Among authors: ariyama h. Cancer Sci. 2023 Jul;114(7):2895-2906. doi: 10.1111/cas.15795. Epub 2023 Mar 31. Cancer Sci. 2023. PMID: 36945114 Free PMC article.
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J; Japan Clinical Oncology Group (JCOG). Morizane C, et al. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. doi: 10.1001/jamaoncol.2022.3395. JAMA Oncol. 2022. PMID: 35980649 Free PMC article. Clinical Trial.
116 results